Anemia is a frequent comorbidity of chronic kidney disease (CKD) and is associated with a
considerable burden because of decreased patient health-related quality of life and …

Anemia is common in patients with chronic kidney disease and is associated with a high
burden of morbidity and adverse clinical outcomes. In 2012, Kidney Disease: Improving …

In chronic kidney disease, anemia and disordered iron homeostasis are prevalent and
associated with significant adverse consequences. In 2012, Kidney Disease: Improving …

Background Roxadustat, an orally administered hypoxia-inducible factor prolyl hydroxylase
inhibitor, is being evaluated for treatment of anaemia of chronic kidney disease (CKD) …

Hypoxia-inducible factor–prolyl hydroxylase domain inhibitors (HIF-PHIs) are a promising
new class of orally administered drugs currently in late-stage global clinical development for …

Background Roxadustat is an orally active hypoxia-inducible factor prolyl hydroxylase
inhibitor for the treatment of chronic kidney disease (CKD) anemia. Methods This Phase 3 …

Background We evaluated the efficacy and safety of roxadustat versus epoetin alfa for the
treatment of chronic kidney disease-related anemia in patients new to dialysis. Methods …

Introduction Roxadustat is an orally administered hypoxia-inducible factor prolyl hydroxylase
inhibitor being developed for the treatment of anemia of chronic kidney disease (CKD). This …

Introduction Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that
stimulates erythropoiesis and improves iron metabolism. We assessed the efficacy and …

Introduction Erythropoiesis-stimulating agents, standard of care for anemia of end-stage
kidney disease, are associated with cardiovascular events. We evaluated the efficacy and …